Nantahala Capital Management LLC Takes $38.88 Million Position in Evolus, Inc. $EOLS

Nantahala Capital Management LLC acquired a new stake in Evolus, Inc. (NASDAQ:EOLS) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 5,602,021 shares of the company’s stock, valued at approximately $38,878,026. Evolus accounts for about 0.0% of Nantahala Capital Management LLC’s investment portfolio, making the stock its 11th biggest holding. Nantahala Capital Management LLC owned about 8.48% of Evolus as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Larson Financial Group LLC lifted its stake in Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after buying an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Evolus during the fourth quarter worth $34,000. Wexford Capital LP bought a new stake in shares of Evolus during the third quarter worth $37,000. Legal & General Group Plc bought a new stake in shares of Evolus during the second quarter worth $40,000. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Evolus during the third quarter worth $48,000. 90.69% of the stock is owned by institutional investors.

Analysts Set New Price Targets

EOLS has been the topic of several research reports. Wall Street Zen raised shares of Evolus from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Evolus in a report on Tuesday. BTIG Research restated a “buy” rating and issued a $13.00 price target on shares of Evolus in a report on Wednesday, June 17th. Finally, Weiss Ratings upgraded Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.50.

Evolus Price Performance

Shares of EOLS opened at $8.88 on Friday. Evolus, Inc. has a twelve month low of $3.86 and a twelve month high of $9.12. The stock has a market capitalization of $586.52 million, a P/E ratio of -17.08 and a beta of 1.35. The company has a 50 day moving average of $7.04 and a 200-day moving average of $5.91.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.